AstraZeneca Stock Leads 3 Cash Flow Picks Worth Watching In Europe

Services led growth across major European economies is starting to firm up, while input costs ease and inflation pressures cool. That mix often pushes investors toward companies where cash flows matter more than headlines. When sentiment shifts, undervalued stocks based on cash flows can attract attention quickly. This article highlights three stocks from the Undervalued Stocks Based On Cash Flows screener that stand out on discounted cash flow value and quality.

The three stocks covered below are just a starting sample, and the full screen identifies 43 more companies with equally compelling cash flow and valuation stories that are not discussed here. To assess that wider group in detail, head straight into the Undervalued Stocks Based On Cash Flows screener to filter, analyze, and focus on the opportunities that best fit your own criteria.

AstraZeneca (LSE:AZN)

Overview: AstraZeneca is a global biopharmaceutical company based in Cambridge that discovers, develops, manufactures, and sells prescription medicines across cancer, cardiovascular, kidney and metabolic diseases, respiratory and immunology, vaccines, and rare diseases. The company has a broad portfolio that includes Tagrisso, Imfinzi, Farxiga and many other therapies used by both primary care and specialist doctors worldwide.

Operations: AstraZeneca generates its revenue predominantly from pharmaceuticals, with about $61.4b coming from prescription medicines.

Market Cap: £186.7b

Investors watching cash flow driven opportunities may find AstraZeneca interesting because it combines a broad, late stage oncology and rare disease pipeline with reported fundamentals such as a 20.8% Return on Equity and 17% net profit margins. Recent regulatory wins in Europe and the US for drugs like Datroway, Enhertu and Etcamah may point to potential new revenue streams. Partnerships in precision oncology and AI supported drug development are intended to keep the pipeline productive. At the same time, reliance on blockbuster products and heavy R&D spend leave the company exposed to patent expiries, price controls, and clinical trial setbacks. The mix of current cash generation, analyst expectations of earnings growth and active deal making, including merger speculation, may make AstraZeneca a stock worth a closer look in a cash flow based framework.

AstraZeneca’s cash rich portfolio and late stage pipeline can look like a growth engine hiding in plain sight. Put that story into context with the analyst forecasts for AstraZeneca and see what the current expectations might be missing.

Build your own cash flow shortlist around AstraZeneca

AstraZeneca and the other two stocks here all surfaced from a single Simply Wall St screen, but the real opportunity is in shaping your own filters. Use our customisable Screener to mix valuation, growth, balance sheet and risk criteria in one place, or tap into our ready made Investing Ideas for curated starting points.

Foresight Group Holdings (LSE:FSG)

Overview: Foresight Group Holdings is a London based asset manager that focuses on infrastructure, renewable energy projects, private equity and listed sustainable funds for institutional and retail investors across the UK, Europe and Australia.

Operations: Foresight Group Holdings generates most of its revenue from Real Assets at about £114.8 million, with around £50.1 million coming from Private Equity, and the bulk of its income sourced from the United Kingdom with meaningful contributions from Australia and Luxembourg.

Market Cap: £547.4 million

Foresight Group Holdings may be of interest if you are looking for a cash flow focused asset manager that reports high profitability and is active in addressing large renewables and infrastructure funding gaps. The company earns fees from £164.9 million of sales, has a net profit margin of 27.7%, and has been buying back shares since 2025, which can support per share metrics over time. Earnings and fee growth depend on continued fundraising and performance fees, which can be uneven from period to period. Heavy exposure to UK and European policy on green energy and rising compliance costs also matters, so this stock often appeals to investors who are willing to weigh strong fundamentals against concentrated regional and regulatory risk.

Foresight Group Holdings sits at the crossroads of infrastructure funding gaps and high margin asset management, yet many investors still treat it as a niche player. Put its reported 27.7% net margin, £164.9 million of sales and share buybacks into context with the analysis report for Foresight Group Holdings to see what the fee mix and policy exposure might really be hinting at next.

BAE Systems (LSE:BA.)

Overview: BAE Systems is a London based defence, aerospace, and security company that supplies combat aircraft, warships, armoured vehicles, munitions, electronic warfare systems, cyber security services, and space hardware to governments around the world.

Operations: BAE Systems generates most of its revenue from Electronic Systems at about £7.8b and Air at about £7.7b, with further contributions from Platforms & Services at about £5.3b, Maritime at about £6.7b, and Cyber & Intelligence at about £2.4b.

Market Cap: £61.1b

BAE Systems combines long term defence programs with a £75b order backlog, growing exposure to higher value areas like electronic warfare, drones, and space hardware, and reported revenue growth that analysts expect to run ahead of the wider UK market. Investors also see a record of cash returns through dividends and buybacks, supported by what is described as high quality earnings and a P/E that sits below many peers. The flip side is real: heavy reliance on a handful of large government contracts, supply chain bottlenecks, ESG pushback, and a relatively leveraged balance sheet can all affect how quickly that backlog converts into cash. If you want exposure to a defence stock where cash flows are a key focus, this is one to study carefully.

BAE Systems sits on a £75b backlog and growing exposure to electronic warfare, drones and space, yet the real story sits inside the analyst forecasts for BAE Systems where one quiet pressure point could change the script.

Seeking Alternatives Before Everyone Else?

Fresh ideas do not stay under the radar for long. Momentum builds, prices move, and the best entries get caught by early movers. Check these screeners and act now.

• Spot resilient cash generators and stress test your defensiveness by scanning the 7 resilient stocks with low risk scores while they are still flying under most investors' watchlists.
• Ride potential breakout infrastructure and grid plays by running the 36 power grid technology and infrastructure stocks before capital surges toward companies upgrading ageing energy networks.
• Track early robotics momentum and see which automation stocks are quietly building orders through the 35 robotics and automation stocks while attention sits elsewhere.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com